机械取栓失败或不完全后动脉内尿激酶的安全性与疗效
该观察性队列研究纳入993例前循环大血管闭塞并接受第二代机械取栓的患者,其中100例在取栓失败或不完全后接受动脉内尿激酶治疗。调整基线特征后,动脉内尿激酶未增加症状性颅内出血风险(aOR 0.81;95%CI 0.31-2.13)或90天死亡率(aOR 0.78;95%CI 0.43-1.40),且与更高的功能独立率相关(aOR 1.93;95%CI 1.11-3.37)。
要点
- 动脉内尿激酶未增加症状性颅内出血和90天死亡风险。
- 动脉内尿激酶组功能独立率更高(aOR 1.93;95%CI 1.11-3.37)。
- 部分再灌注患者中60.4%出现早期再灌注改善。
核心结论
- 在选定患者中,机械取栓期间或之后辅助动脉内尿激酶是安全的,并改善血管造影再灌注。
- 研究认为值得在多中心前瞻性登记或随机临床试验中系统评估该方法。
研究设计与样本
- 观察性队列研究,数据来自三级卒中中心前瞻性登记,纳入2010年1月1日至2017年8月4日接受第二代机械取栓的连续患者。
- 筛查1274例,69例拒绝参与,993例符合前循环大血管闭塞的观察性研究入选标准并纳入最终分析。
- 100例患者在机械取栓失败或不完全后接受手动微导管注射动脉内尿激酶。
主要发现
- 动脉内尿激酶组症状性颅内出血调整OR为0.81(95%CI 0.31-2.13),90天死亡率调整OR为0.78(95%CI 0.43-1.40)。
- 在53例部分或近完全再灌注并接受动脉内尿激酶的患者中,32例(60.4%)出现早期再灌注改善,18例(34.0%)TICI分级改善。
- 动脉内尿激酶组功能独立率更高,调整OR为1.93(95%CI 1.11-3.37)。
关键数值与推荐
- 主要安全结局为症状性颅内出血,采用Prolyse in Acute Cerebral Thromboembolism II标准。
- 功能独立定义为90天改良Rankin量表评分≤2。
- 疗效通过血管造影应用Thrombolysis in Cerebral Infarction(TICI)量表评估。
临床怎么用
- 对于机械取栓失败或不完全再灌注的选定前循环大血管闭塞患者,可考虑辅助动脉内尿激酶以改善再灌注。
- 临床应用需权衡个体化选择,因证据来自观察性研究,尚待随机临床试验验证。
局限性
- 为观察性队列研究,存在选择偏倚,动脉内尿激酶组患者基线TICI分级可能更差。
- 原文未报告多中心外部验证或随机对照数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Achieving complete reperfusion is a key determinant of good outcome in patients treated with mechanical thrombectomy (MT). However, data on treatments geared toward improving reperfusion after incomplete MT are sparse. OBJECTIVE: To determine whether administration of intra-arterial urokinase is safe and improves reperfusion after failed or incomplete MT. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study included a consecutive sample of patients treated with second-generation MT from January 1, 2010, through August 4, 2017. Data were collected from the prospective registry of a tertiary care stroke center. Of 1274 patients screened, 69 refused to participate, and 993 met the observational studies inclusion criteria of a large vessel occlusion in the anterior circulation. Data were analyzed from September 1, 2017, through September 20, 2019. INTERVENTION: One hundred patients received intra-arterial urokinase after failed or incomplete MT using manual microcatheter injections. MAIN OUTCOMES AND MEASURES: Primary safety outcome was the occurrence of symptomatic intracranial hemorrhage (sICH) according to the Prolyse in Acute Cerebral Thromboembolism II criteria. Secondary end points included 90-day mortality and 90-day functional independence (defined as modified Rankin Scale score of ≤2). Efficacy was evaluated angiographically, applying the Thrombolysis in Cerebral Infarction (TICI) scale. RESULTS: After exclusion of patients with posterior circulation strokes and those treated with intra-arterial thrombolytics only, 993 patients were included in the final analyses (median age, 74.6 [interquartile range, 62.6-82.2] years; 505 [50.9%] women). Additional intra-arterial urokinase was administered in 100 patients (10.1%). The most common reason for administering intra-arterial urokinase was incomplete reperfusion (TICI<3) after MT (53 [53.0%]). After adjusting for baseline characteristics underlying case selection, intra-arterial urokinase was not associated with an increased risk of sICH (adjusted odds ratio [aOR], 0.81; 95% CI, 0.31-2.13) or 90-day mortality (aOR, 0.78; 95% CI, 0.43-1.40). Among 53 cases of partial or near-complete reperfusion and treated with intra-arterial urokinase, 32 (60.4%) had early reperfusion improvement, and 18 of 53 (34.0%) had an improvement in TICI grade. Correspondingly, patients treated with intra-arterial urokinase had higher rates of functional independence after adjusting for the selection bias favoring a priori poor TICI grades in the intra-arterial urokinase group (aOR, 1.93; 95% CI, 1.11-3.37). CONCLUSIONS AND RELEVANCE: In selected patients, adjunctive treatment with intra-arterial urokinase during or after MT was safe and improved angiographic reperfusion. Systemic evaluation of this approach in a multicenter prospective registry or a randomized clinical trial seems warranted.
引用
- Kaesmacher J, Bellwald S, Dobrocky T, et al. Safety and Efficacy of Intra-arterial Urokinase After Failed, Unsuccessful, or Incomplete Mechanical Thrombectomy in Anterior Circulation Large-Vessel Occlusion Stroke. JAMA Neurol. 2020. PMID: 31816018. doi:10.1001/jamaneurol.2019.4192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。